Drug Trial Radar · NCT05751967
Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Feb 22, 2023
Primary completion
Dec 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Xijing Hospital of Digestive DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Current treatment guidelines recommend ursodeoxycholic acid (UDCA) as the first-line treatment for new-diagnosed primary biliary cholangitis (PBC) patients. However, up to 40% patients are insensitive to UDCA monotherapy, and evaluation of UDCA response at 12 months may result in long period of ineffective treatment. We aimed to develop a new criterion to reliably identify non-response patients much earlier. Recently, our team designed and validated a new early criterion for distinguishing high-risk PBC patients in a Chinese population for the first time. Our data indicated that PBC patients with ALP ≤ 2.5 × ULN, AST ≤ 2 × ULN, and TBIL ≤ 1 × ULN (Xi'an criterion) after 1 month UDCA treatment were likely to have better prognosis. It can be readily applied in the rapid identification of PBC patients who require additional therapeutic approaches. However, whether it is reasonable to apply it to the response definition of clinical research, and the guidance of PBC management and choice of second-line treatment, further research is needed.
Conditions
- Primary Biliary Cholangitis
Interventions
Placebo Combined With Ursodeoxycholic AcidDrug
1 tablet/ day
Fenofibrate Combined With Ursodeoxycholic AcidDrug
200 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with complete biochemical responseTime frame: 48 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University General Hospital
Tianjin, China · Recruiting
The second hospital of Lanzhou University
Lanzhou, Gansu, China · Recruiting
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Ying han
Xi'an, Shaanxi, China · Recruiting
Sichuan Provincial People's Hospital,
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.